The Pharmaceutical Journal·3 min read·hard
NICE draft guidance recommends finerenone for type of chronic heart failure
✦AI Summary
NICE has issued final draft guidance recommending the use of finerenone for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The drug is presented as a potential alternative to spironolactone, offering a different side-effect profile for patients.
Up to 280,000 people in England could be eligible for a new drug to treat heart failure with preserved or mildly reduced ejection fraction, the National Institute for Health and Care Excellence (NICE) has said.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in